Similar articles

• Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.

  Lichtenstein GR. Lichtenstein GR. Am J Gastroenterol. 2005 Jul;100(7):1433-5. doi: 10.1111/j.1572-0241.2005.50622_1.x. Am J Gastroenterol. 2005. PMID: 15984959 Review. No abstract available.
• Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.

  Sandborn WJ. Sandborn WJ. Gastroenterology. 2003 Apr;124(4):1140-5. doi: 10.1053/gast.2003.50182. Gastroenterology. 2003. PMID: 12671907 Review. No abstract available.
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Baert F, et al. N Engl J Med. 2003 Feb 13;348(7):601-8. doi: 10.1056/NEJMoa020888. N Engl J Med. 2003. PMID: 12584368 Clinical Trial.
• Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.

  Hanauer SB. Hanauer SB. Am J Gastroenterol. 2005 Jul;100(7):1438-9. doi: 10.1111/j.1572-0241.2005.50622_3.x. Am J Gastroenterol. 2005. PMID: 15984961 No abstract available.
• Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

  Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Hyams J, et al. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.